Objective To elucidate whether plasma soluble receptor for advanced glycation end products (sRAGE) is the biochemical markers indicating coronary artery disease and coronary artery disease with acute myocardial infarction (AMI).
Method Plasma levels of sRAGE was determined by enzyme linked immunoabsorbent assay in patients who came from Cardiology Department of Tiantan Hospital form March to May 2009 categorised as group I (non-CAD subjects), group II (CAD without myocardial infarction subjects), and group III (CAD with AMI subjects).
Results Plasma levels of sRAGE was higher in group III than in group II (p<0.01) and in group I (p<0.01). The levels of sRAGE between group II and group I were of no statistical difference (p>0.05). Further more, to evaluate whether sRAGE is the biochemical markers indicating the AMI in CAD patients, ROC curve was used, and area under the curve was 0.855(p=0.000).
Conclusion sRAGE may be new biochemical markers indicating AMI in the patients with coronary artery disease. The diagnostic sensitivity of sRAGE is 75% and specificity is 86.4%.
- coronary artery disease, biochemical marker